Biotechnology company pioneering immuno-neurology treatments for neurodegenerative diseases.
Alector, Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to advancing therapies aimed at combating neurodegenerative diseases. At the forefront of its product portfolio is AL001, currently in Phase III clinical trials. This therapeutic targets immune activity within the brain, focusing on genetic links associated with multiple neurodegenerative disorders including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Concurrently, AL101 is undergoing Phase I clinical trials for the treatment of various neurodegenerative diseases, notably Alzheimer's and Parkinson's diseases.
The company's innovative pipeline also includes AL002, currently in Phase II clinical trials specifically designed for Alzheimer's disease treatment, and AL003, which is undergoing Phase I clinical trials to address Alzheimer's disease. Alector's research extends to AL044, a product candidate targeting MS4A4A, a genetic risk factor associated with Alzheimer's disease progression.
Alector, Inc. has established strategic collaborations to bolster its research and development efforts. Notably, it collaborates with Adimab, LLC for the development of antibodies crucial to its therapeutic initiatives. Furthermore, a significant partnership with GlaxoSmithKline plc focuses on the joint development and commercialization of monoclonal antibodies, including AL001, AL002, and AL101, aimed at treating neurodegenerative diseases.
Founded in 2013 and headquartered in South San Francisco, California, Alector, Inc. continues to expand its pioneering research in neurodegenerative diseases, leveraging its expertise to potentially transform treatment options for patients worldwide.